Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNF185 antisense RNA 1 (RNF185-AS1) is a long non-coding RNA (lncRNA) transcribed antisense to the RNF185 gene. As a non-coding transcript, RNF185-AS1 does not encode a protein but may play a regulatory role in gene expression. Recent research has shown that RNF185-AS1 is upregulated in papillary thyroid carcinoma and its increased expression promotes proliferation, migration, and invasion of cancer cells, suggesting it may contribute to tumor progression[4]. However, there are no approved drugs, biomarkers, or established therapeutic interventions directly targeting RNF185-AS1. Its activities are most likely exerted through modulating expression of target genes—either that of the sense RNF185 gene or others—in a manner typical of lncRNA-mediated regulation. Note: - The search results primarily detail RNF185 (the protein-coding E3 ubiquitin ligase; a classical therapeutic target) and not RNF185-AS1 (the lncRNA in question), except for one specific mention in cancer context[4]. - If the intention was to retrieve information on RNF185 (the protein-coding gene or its product), further clarification would yield a different answer with expanded therapeutic relevance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNF185 antisense RNA 1 (RNF185-AS1).